Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Keith Sacco

Allergy & Immunology Phoenix, AZ Medical Doctor

NPI 1780049759 CMS profile 4216229

1919 E Thomas Rd, Phoenix, AZ 85016

Open in the dashboard

General payments

$118,049

178 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$247,667 paid to institutions, not to them · program years 2024–2025

Through program year 2025, Keith Sacco of Phoenix, AZ is reported in the CMS Open Payments database as having received $118,049 across 178 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $247,667 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 94th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $38,841 4
2024 General $263 5
2023 General $77,908 151
2022 General $1,037 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Keith Sacco
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Keith Sacco were reported at $38,841. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Keith Sacco Allergy & Immunology median Middle half National median
2019 $0 $594 $163–$1,512 $163
2020 $0 $426 $106–$1,233 $114
2021 $0 $638 $157–$1,708 $132
2022 $1,037 $790 $205–$1,961 $149
2023 $77,908 $852 $220–$2,147 $160
2024 $263 $865 $203–$2,267 $164
2025 $38,841 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Pharming Healthcare, Inc. $87,569 90 payments
  2. Sumitomo Pharma America, Inc. $15,912 25 payments
  3. Horizon Therapeutics plc $13,051 23 payments
  4. CSL Behring $430 9 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $359 13 payments
  6. Genzyme Corporation $146 2 payments
  7. AbbVie, Inc. $125 1 payment
  8. ADMA BioManufacturing LLC $97 1 payment
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $66 2 payments
  10. Amgen Inc. $56 1 payment
  11. Other $237 11 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Consulting Fee $86,875 17 payments
  2. Honoraria $10,835 3 payments
  3. Travel and Lodging $10,709 58 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $5,790 1 payment
  5. Food and Beverage $3,840 99 payments
Products named General payments · program years 2022–2025
  1. JOENJA $87,251 84 payments
  2. RETHYMIC $15,912 25 payments
  3. ACTIMMUNE Actimmune $12,948 21 payments
  4. Hizentra $370 7 payments
  5. CUVITRU $343 11 payments
  6. RUCONEST $319 6 payments
  7. DUPIXENT Immunology $165 3 payments
  8. RINVOQ $125 1 payment
  9. ACTIMMUNE Bone/Inflammation/Rare Disease $56 1 payment
  10. DUPIXENT Inflammation And Immunology $44 1 payment
  11. Other $267 15 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

178 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record